Actinium Pharmaceuticals, Inc.
ATNM
$1.25
$0.021.29%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | 11.11% | -- |
| Total Revenue | -- | -- | -- | 11.11% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 11.11% | -- |
| SG&A Expenses | -56.62% | -55.81% | 25.98% | 35.10% | 47.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.29% | -47.92% | -13.73% | -16.90% | -5.43% |
| Operating Income | 121.60% | 48.11% | 13.95% | 16.95% | 5.27% |
| Income Before Tax | 127.56% | 48.43% | 11.39% | 15.44% | 3.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 127.56% | 48.43% | 11.39% | 15.44% | 3.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 127.56% | 48.43% | 11.39% | 15.44% | 3.72% |
| EBIT | 121.60% | 48.11% | 13.95% | 16.95% | 5.27% |
| EBITDA | 123.56% | 48.90% | 14.17% | 17.22% | 5.36% |
| EPS Basic | 127.10% | 48.95% | 14.70% | 20.79% | 13.28% |
| Normalized Basic EPS | 127.11% | 48.95% | 14.70% | 20.81% | 13.30% |
| EPS Diluted | 127.10% | 48.95% | 14.70% | 20.79% | 13.28% |
| Normalized Diluted EPS | 127.08% | 48.95% | 14.70% | 20.81% | 13.30% |
| Average Basic Shares Outstanding | 0.29% | 1.01% | 3.76% | 7.13% | 10.84% |
| Average Diluted Shares Outstanding | 0.30% | 1.01% | 3.76% | 7.13% | 10.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |